Fludarabine | Aplastic Anemia and MDS International Foundation

Fludarabine

An antineoplastic agent, this medicine works by slowing or stopping the growth of cancer cells.
Brand name: 
Fludara

The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in combination with other medicines for treating bone marrow failure.

Related Clinical Trials

Clinical Trial Status Age Group
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting 18 years and older
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Recruiting up to 75 years
Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Recruiting 2 years to 70 years
AML Therapy With Irradiated Allogeneic Cells Recruiting 18 years and older
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation Not yet recruiting 18 years and older
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR Recruiting
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor Recruiting up to 19 years old
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting up to 22 years
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting Up to 22 years
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome Recruiting 18 years to 60 years
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. Recruiting 18 years to 70 years
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Recruiting 1 to 80 years
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Recruiting
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting not provided
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Recruiting 11 years to 90 years
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Recruiting up to 69 years
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting 6 months to 45 years
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Recruiting not specified
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Recruiting
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Recruiting
Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Recruiting up to 60 years
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting 18 and older
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Recruiting
GVAX vs. Placebo for MDS/AML After Allo HSCT Recruiting 18 years and older
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Recruiting Up to 70 years
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia Recruiting up to 3 years
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies Recruiting up to 69 years
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA) Recruiting 3 months and older
Intra-Osseous Co-Transplant of UCB and hMSC Recruiting 18 to 75 years
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Sy Recruiting 18 years and older
LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) Not yet recruiting 18 years and older
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Recruiting up to 55 years
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Recruiting 7 years to 65 years
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Recruiting up to 75 years
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP) Recruiting up to 75 years
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting up to 24 years
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI) Recruiting 18 to 70 years
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita Recruiting Up to 30 years
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Recruiting 18 year and older
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting 18 years and older
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Recruiting up to 74 years
Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT (RIC HSCT NMD) Recruiting 2 months to 35 years
Reduced Intensity Double Umbilical Cord Blood Transplantation Recruiting 18 years to 70 years
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS Recruiting 1 month to 22 years
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting 18 years and older
Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD Recruiting 14 years to 60 years
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children Recruiting up to 21 years
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Recruiting up to 24 years
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Recruiting 6 monthgs to 75 years
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Recruiting 2 to 35 years
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting 18 years to 70 yeasr
TBI Dose De-escalation for Fanconi Anemia Recruiting
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Recruiting 12 years to 60 years
Total Marrow Irradiation for Refractory Acute Leukemia Recruiting up to 55 years
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Recruiting up to 73 years
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Available up to 73 years
Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting up to 70 years
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting up to 65 years
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting up to 75 years
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting 6 months to 45 years
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting 18 years and older

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.